Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors
Sarah P. Blagden(Churchill Hospital), W.P. Steward(Leicester Royal Infirmary), Alastair Greystoke(Newcastle University), Gerhardt Attard(Royal Marsden NHS Foundation Trust), P. Fong(Leicester Royal Infirmary), Sheikh Ahmed(Leicester Royal Infirmary), A. Jenner(Daiichi Sankyo (United Kingdom)), Adam G. Thomas(Leicester Royal Infirmary)
Cited by 3
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2023|317